Download PDF
Semin Thromb Hemost 2014; 40(07): 774-784
DOI: 10.1055/s-0034-1387922
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Inherited Macrothrombocytopenias

David John Rabbolini
1   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
2   Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia
,
Marie Christine Morel-Kopp
1   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
2   Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia
,
William Stevenson
1   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
2   Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia
,
Christopher Morice Ward
1   Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia
2   Northern Blood Research Centre, Kolling Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
31 August 2014 (online)

    Permissions and Reprints

Abstract

Inherited macrothrombocytopenias are a clinically heterogeneous group of disorders, many of which cause moderate-to-severe bleeding tendencies in affected individuals, but which remain under-recognized and are frequently misdiagnosed as immune thrombocytopenia purpura. Diagnostic strategies to date have included a predominant phenotypic approach. The emergence of genetic testing and the implementation of next generation sequencing strategies in the investigation and diagnosis of these disorders have broadened our understanding of their pathogenesis, classification, and presentation. This review describes the increasingly expanding group of recognized inherited macrothrombocytopenias and highlights their pathophysiology and the role of phenotypic and genetic testing in their description and diagnosis.

Keywords

inherited macrothrombo-cytopenia - next generation sequencing - whole exome sequencing - transcriptional factors - GFI1B
 

  • References

  • 1 Savoia A, De Rocco D, Panza E , et al. Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 2010; 103 (4) 826-832
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Novelli EM, Ragni MV. Genetics of bleeding disorders in women. Semin Thromb Hemost 2008; 34 (6) 509-519
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Jones ML, Murden SL, Bem D , et al; UK GAPP study group. Rapid genetic diagnosis of heritable platelet function disorders with next-generation sequencing: proof-of-principle with Hermansky-Pudlak syndrome. J Thromb Haemost 2012; 10 (2) 306-309
    CrossrefPubMedSearch in Google Scholar
  • 4 Kunishima S, Okuno Y, Yoshida K , et al. ACTN1 mutations cause congenital macrothrombocytopenia. Am J Hum Genet 2013; 92 (3) 431-438
    CrossrefPubMedSearch in Google Scholar
  • 5 Stevenson WS, Morel-Kopp MC, Chen Q , et al. GFI1B mutation causes a bleeding disorder with abnormal platelet function. J Thromb Haemost 2013; 11 (11) 2039-2047
    CrossrefPubMedSearch in Google Scholar
  • 6 Monteferrario D, Bolar NA, Marneth AE , et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med 2014; 370 (3) 245-253
    CrossrefPubMedSearch in Google Scholar
  • 7 Althaus K, Greinacher A. MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis. Transfus Med Hemother 2010; 37 (5) 260-267
    PubMedSearch in Google Scholar
  • 8 Thon JN, Italiano Jr JE. Does size matter in platelet production?. Blood 2012; 120 (8) 1552-1561
    CrossrefPubMedSearch in Google Scholar
  • 9 Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011; 154 (2) 161-174
    CrossrefPubMedSearch in Google Scholar
  • 10 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35 (2) 189-203
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Hegglin R. Gleichzeitige konstitutionelle Veranderungen an Neutrophilen und Thrombozyten. Helv Med Acta 1945; 12: 439-440
    PubMedSearch in Google Scholar
  • 12 Epstein CJ, Sahud MA, Piel CF , et al. Hereditary macrothrombocytopathia, nephritis and deafness. Am J Med 1972; 52 (3) 299-310
    CrossrefPubMedSearch in Google Scholar
  • 13 Peterson LC, Rao KV, Crosson JT, White JG. Fechtner syndrome—a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia. Blood 1985; 65 (2) 397-406
    PubMedSearch in Google Scholar
  • 14 Greinacher A, Nieuwenhuis HK, White JG. Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut 1990; 61 (5) 282-288
    CrossrefPubMedSearch in Google Scholar
  • 15 Hodge T, Cope MJ. A myosin family tree. J Cell Sci 2000; 113 (Pt 19) 3353-3354
    PubMedSearch in Google Scholar
  • 16 Niederman R, Pollard TD. Human platelet myosin. II. In vitro assembly and structure of myosin filaments. J Cell Biol 1975; 67 (1) 72-92
    CrossrefPubMedSearch in Google Scholar
  • 17 Pecci A, Panza E, Pujol-Moix N , et al. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 2008; 29 (3) 409-417
    CrossrefPubMedSearch in Google Scholar
  • 18 Pecci A, Bozzi V, Panza E , et al. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells. Thromb Haemost 2011; 106 (4) 693-704
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Pecci A, Malara A, Badalucco S , et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009; 102 (1) 90-96
    PubMedSearch in Google Scholar
  • 20 Pecci A, Canobbio I, Balduini A , et al. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations. Hum Mol Genet 2005; 14 (21) 3169-3178
    CrossrefPubMedSearch in Google Scholar
  • 21 Noris P, Spedini P, Belletti S, Magrini U, Balduini CL. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med 1998; 104 (4) 355-360
    CrossrefPubMedSearch in Google Scholar
  • 22 Yi Y, Sen Zhang G, Xu M , et al. Analysis of clinical manifestations, mutant gene and encoded protein in two Chinese MYH9-related disease families. Clin Chim Acta 2006; 373 (1-2) 49-54
    CrossrefPubMedSearch in Google Scholar
  • 23 Pecci A, Gresele P, Klersy C , et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116 (26) 5832-5837
    CrossrefPubMedSearch in Google Scholar
  • 24 Canobbio I, Noris P, Pecci A, Balduini A, Balduini CL, Torti M. Altered cytoskeleton organization in platelets from patients with MYH9-related disease. J Thromb Haemost 2005; 3 (5) 1026-1035
    CrossrefPubMedSearch in Google Scholar
  • 25 Kunishima S, Kobayashi R, Itoh TJ, Hamaguchi M, Saito H. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009; 113 (2) 458-461
    PubMedSearch in Google Scholar
  • 26 Freson K, De Vos R, Wittevrongel C , et al. The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood 2005; 106 (7) 2356-2362
    CrossrefPubMedSearch in Google Scholar
  • 27 Gieger C, Radhakrishnan A, Cvejic A , et al. New gene functions in megakaryopoiesis and platelet formation. Nature 2011; 480 (7376) 201-208
    CrossrefPubMedSearch in Google Scholar
  • 28 Guéguen P, Rouault K, Chen JM , et al. A missense mutation in the alpha-actinin 1 gene (ACTN1) is the cause of autosomal dominant macrothrombocytopenia in a large French family. PLoS ONE 2013; 8 (9) e74728
    CrossrefPubMedSearch in Google Scholar
  • 29 Nurden P, Debili N, Coupry I , et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood 2011; 118 (22) 5928-5937
    CrossrefPubMedSearch in Google Scholar
  • 30 Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat Cell Biol 2004; 6 (11) 1034-1038
    CrossrefPubMedSearch in Google Scholar
  • 31 Falet H. New insights into the versatile roles of platelet FlnA. Platelets 2013; 24 (1) 1-5
    CrossrefPubMedSearch in Google Scholar
  • 32 Berrou E, Adam F, Lebret M , et al. Heterogeneity of platelet functional alterations in patients with filamin A mutations. Arterioscler Thromb Vasc Biol 2013; 33 (1) e11-e18
    CrossrefPubMedSearch in Google Scholar
  • 33 López JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91 (12) 4397-4418
    PubMedSearch in Google Scholar
  • 34 Savoia A, Pastore A, De Rocco D , et al. Clinical and genetic aspects of Bernard-Soulier syndrome: searching for genotype/phenotype correlations. Haematologica 2011; 96 (3) 417-423
    CrossrefPubMedSearch in Google Scholar
  • 35 Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Inherited traits affecting platelet function. Blood Rev 2008; 22 (3) 155-172
    CrossrefPubMedSearch in Google Scholar
  • 36 Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model. Exp Hematol 2002; 30 (4) 352-360
    CrossrefPubMedSearch in Google Scholar
  • 37 Savoia A, Balduini CL, Savino M , et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97 (5) 1330-1335
    CrossrefPubMedSearch in Google Scholar
  • 38 Noris P, Perrotta S, Bottega R , et al. Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIbα (Bolzano mutation). Haematologica 2012; 97 (1) 82-88
    CrossrefPubMedSearch in Google Scholar
  • 39 Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost 2013; 11 (6) 1006-1019
    CrossrefPubMedSearch in Google Scholar
  • 40 Diz-Kücükkaya R, López JA. Inherited disorders of platelets: membrane glycoprotein disorders. Hematol Oncol Clin North Am 2013; 27 (3) 613-627
    CrossrefPubMedSearch in Google Scholar
  • 41 Thon JN, Macleod H, Begonja AJ , et al. Microtubule and cortical forces determine platelet size during vascular platelet production. Nat Commun 2012; 3: 852
    CrossrefPubMedSearch in Google Scholar
  • 42 Balduini A, Malara A, Pecci A , et al. Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano. J Thromb Haemost 2009; 7 (3) 478-484
    CrossrefPubMedSearch in Google Scholar
  • 43 Strassel C, Eckly A, Léon C , et al. Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome. Haematologica 2009; 94 (6) 800-810
    CrossrefPubMedSearch in Google Scholar
  • 44 Harrison P, Mackie I, Mumford A , et al; British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155 (1) 30-44
    CrossrefPubMedSearch in Google Scholar
  • 45 Cooney KA, Ginsburg D. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets. Blood 1996; 87 (6) 2322-2328
    PubMedSearch in Google Scholar
  • 46 Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993; 81 (7) 1787-1791
    CrossrefPubMedSearch in Google Scholar
  • 47 Takahashi H, Murata M, Moriki T , et al. Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 1995; 85 (3) 727-733
    PubMedSearch in Google Scholar
  • 48 Othman M, Notley C, Lavender FL , et al. Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease. Blood 2005; 105 (11) 4330-4336
    CrossrefPubMedSearch in Google Scholar
  • 49 Moriki T, Murata M, Kitaguchi T , et al. Expression and functional characterization of an abnormal platelet membrane glycoprotein Ib alpha (Met239 —> Val) reported in patients with platelet-type von Willebrand disease. Blood 1997; 90 (2) 698-705
    PubMedSearch in Google Scholar
  • 50 Hamilton A, Ozelo M, Leggo J , et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost 2011; 105 (3) 501-508
    Thieme ConnectPubMedSearch in Google Scholar
  • 51 Woods AI, Sanchez-Luceros A, Bermejo E , et al. Identification of p.W246L as a novel mutation in the GP1BA gene responsible for platelet-type von Willebrand disease. Semin Thromb Hemost 2014; 40 (2) 151-160
    Thieme ConnectPubMedSearch in Google Scholar
  • 52 Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia 1999; 5 (5) 313-317
    CrossrefPubMedSearch in Google Scholar
  • 53 Favaloro EJ, Patterson D, Denholm A , et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007; 139 (4) 623-626
    CrossrefPubMedSearch in Google Scholar
  • 54 Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010; 48 (5) 579-598
    CrossrefPubMedSearch in Google Scholar
  • 55 Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011; 127 (Suppl. 02) S17-S21
    PubMedSearch in Google Scholar
  • 56 Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K. RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007; 98 (2) 346-358
    PubMedSearch in Google Scholar
  • 57 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?. Semin Thromb Hemost 2008; 34 (1) 113-127
    Thieme ConnectPubMedSearch in Google Scholar
  • 58 Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010; 8 (1) 6-12
    CrossrefPubMedSearch in Google Scholar
  • 59 James PD, Notley C, Hegadorn C , et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109 (1) 145-154
    CrossrefPubMedSearch in Google Scholar
  • 60 Federici AB, Mannucci PM, Castaman G , et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113 (3) 526-534
    CrossrefPubMedSearch in Google Scholar
  • 61 Poon MC, Rand ML, Jackson SC. 2B or not to be—the 45-year saga of the Montreal Platelet Syndrome. Thromb Haemost 2010; 104 (5) 903-910
    Thieme ConnectPubMedSearch in Google Scholar
  • 62 Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 2009; 113 (14) 3348-3351
    CrossrefPubMedSearch in Google Scholar
  • 63 Nurden P, Chretien F, Poujol C, Winckler J, Borel-Derlon A, Nurden A. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol 2000; 110 (3) 704-714
    CrossrefPubMedSearch in Google Scholar
  • 64 Nurden P, Debili N, Vainchenker W , et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 2006; 108 (8) 2587-2595
    CrossrefPubMedSearch in Google Scholar
  • 65 Nurden AT, Nurden P. Inherited thrombocytopenias. Haematologica 2007; 92 (9) 1158-1164
    CrossrefPubMedSearch in Google Scholar
  • 66 Nurden P, Gobbi G, Nurden A , et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010; 115 (13) 2649-2656
    CrossrefPubMedSearch in Google Scholar
  • 67 Liang HP, Morel-Kopp MC, Curtin J , et al. Heterozygous loss of platelet glycoprotein (GP) Ib-V-IX variably affects platelet function in velocardiofacial syndrome (VCFS) patients. Thromb Haemost 2007; 98 (6) 1298-1308
    Thieme ConnectPubMedSearch in Google Scholar
  • 68 Pallotta R, Evangelista V, Margaglione M, Bucci I, Saponari A. Macrothrombocytopenia in velocardiofacial syndrome. J Thromb Haemost 2005; 3 (3) 601-603
    CrossrefPubMedSearch in Google Scholar
  • 69 Van Geet C, Devriendt K, Eyskens B, Vermylen J, Hoylaerts MF. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998; 44 (4) 607-611
    CrossrefPubMedSearch in Google Scholar
  • 70 Ducrou W, Kimber RJ. Stomatocytes, haemolytic anaemia and abdominal pain in Mediterranean migrants. Some examples of a new syndrome?. Med J Aust 1969; 2 (22) 1087-1091
    PubMedSearch in Google Scholar
  • 71 Gunay-Aygun M, Zivony-Elboum Y, Gumruk F , et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010; 116 (23) 4990-5001
    CrossrefPubMedSearch in Google Scholar
  • 72 Whiteheart SW. α-Granules at the BEACH. Blood 2013; 122 (19) 3247-3248
    CrossrefPubMedSearch in Google Scholar
  • 73 Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007; 21 (1) 21-36
    CrossrefPubMedSearch in Google Scholar
  • 74 Albers CA, Cvejic A, Favier R , et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011; 43 (8) 735-737
    CrossrefPubMedSearch in Google Scholar
  • 75 Gunay-Aygun M, Falik-Zaccai TC, Vilboux T , et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet 2011; 43 (8) 732-734
    CrossrefPubMedSearch in Google Scholar
  • 76 Bottega R, Pecci A, De Candia E , et al. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and α-granule deficiency. Haematologica 2013; 98 (6) 868-874
    CrossrefPubMedSearch in Google Scholar
  • 77 Lo B, Li L, Gissen P , et al. Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 2005; 106 (13) 4159-4166
    CrossrefPubMedSearch in Google Scholar
  • 78 Kahr WH, Lo RW, Li L , et al. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice. Blood 2013; 122 (19) 3349-3358
    CrossrefPubMedSearch in Google Scholar
  • 79 Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; 35 (2) 158-167
    Thieme ConnectPubMedSearch in Google Scholar
  • 80 Zon LI, Tsai SF, Burgess S, Matsudaira P, Bruns GA, Orkin SH. The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome. Proc Natl Acad Sci U S A 1990; 87 (2) 668-672
    CrossrefPubMedSearch in Google Scholar
  • 81 Tsang AP, Visvader JE, Turner CA , et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 1997; 90 (1) 109-119
    CrossrefPubMedSearch in Google Scholar
  • 82 Hong W, Nakazawa M, Chen YY , et al. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J 2005; 24 (13) 2367-2378
    CrossrefPubMedSearch in Google Scholar
  • 83 Ciovacco WA, Raskind WH, Kacena MA. Human phenotypes associated with GATA-1 mutations. Gene 2008; 427 (1-2) 1-6
    CrossrefPubMedSearch in Google Scholar
  • 84 Tsai SF, Martin DI, Zon LI, D'Andrea AD, Wong GG, Orkin SH. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 1989; 339 (6224) 446-451
    CrossrefPubMedSearch in Google Scholar
  • 85 Freson K, Devriendt K, Matthijs G , et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001; 98 (1) 85-92
    CrossrefPubMedSearch in Google Scholar
  • 86 Balduini CL, Pecci A, Loffredo G , et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost 2004; 91 (1) 129-140
    PubMedSearch in Google Scholar
  • 87 Doerks T, Copley RR, Schultz J, Ponting CP, Bork P. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res 2002; 12 (1) 47-56
    CrossrefPubMedSearch in Google Scholar
  • 88 Vassen L, Okayama T, Möröy T. Gfi1b:green fluorescent protein knock-in mice reveal a dynamic expression pattern of Gfi1b during hematopoiesis that is largely complementary to Gfi1. Blood 2007; 109 (6) 2356-2364
    CrossrefPubMedSearch in Google Scholar
  • 89 Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN. The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal. Mol Cell Biol 1996; 16 (11) 6263-6272
    PubMedSearch in Google Scholar
  • 90 Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Duménil D. Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood 2010; 115 (14) 2784-2795
    CrossrefPubMedSearch in Google Scholar
  • 91 Wilson NK, Foster SD, Wang X , et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 2010; 7 (4) 532-544
    CrossrefPubMedSearch in Google Scholar
  • 92 Balduini CL, Savoia A. Genetics of familial forms of thrombocytopenia. Hum Genet 2012; 131 (12) 1821-1832
    CrossrefPubMedSearch in Google Scholar
  • 93 Kunishima S, Saito H. Congenital macrothrombocytopenias. Blood Rev 2006; 20 (2) 111-121
    CrossrefPubMedSearch in Google Scholar
  • 94 Raslova H, Komura E, Le Couédic JP , et al. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest 2004; 114 (1) 77-84
    CrossrefPubMedSearch in Google Scholar
  • 95 Lu K, Lee MH, Hazard S , et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001; 69 (2) 278-290
    CrossrefPubMedSearch in Google Scholar
  • 96 Stewart GW, Makris M. Mediterranean macrothrombocytopenia and phytosterolaemia/sitosterolaemia. Haematologica 2008; 93 (2) e29
    CrossrefPubMedSearch in Google Scholar
  • 97 Stewart GW, Lloyd J, Pegel K. Mediterranean stomatocytosis/macrothrombocytopenia: update from Adelaide, Australia. Br J Haematol 2006; 132 (5) 660-661
    CrossrefPubMedSearch in Google Scholar
  • 98 McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35 (2) 168-180
    Thieme ConnectPubMedSearch in Google Scholar
  • 99 Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Rev Hematol 2012; 5 (5) 487-503
    CrossrefPubMedSearch in Google Scholar
  • 100 Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P. Glanzmann thrombasthenia-like syndromes associated with Macrothrombocytopenias and mutations in the genes encoding the αIIbβ3 integrin. Semin Thromb Hemost 2011; 37 (6) 698-706
    Thieme ConnectPubMedSearch in Google Scholar
  • 101 Beer JH, Rabaglio M, Berchtold P , et al. Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction. Blood 1993; 82 (3) 820-829
    PubMedSearch in Google Scholar
  • 102 Yufu Y, Ideguchi H, Narishige T , et al. Familial macrothrombocytopenia associated with decreased glycosylation of platelet membrane glycoprotein IV. Am J Hematol 1990; 33 (4) 271-273
    CrossrefPubMedSearch in Google Scholar
  • 103 Yamamoto N, Ikeda H, Tandon NN , et al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). Blood 1990; 76 (9) 1698-1703
    PubMedSearch in Google Scholar
  • 104 Yamamoto N, Akamatsu N, Yamazaki H, Tanoue K. Normal aggregations of glycoprotein IV (CD36)-deficient platelets from seven healthy Japanese donors. Br J Haematol 1992; 81 (1) 86-92
    CrossrefPubMedSearch in Google Scholar
  • 105 Becker PS, Clavell LA, Beardsley DS. Giant platelets with abnormal surface glycoproteins: a new familial disorder associated with mitral valve insufficiency. J Pediatr Hematol Oncol 1998; 20 (1) 69-73
    CrossrefPubMedSearch in Google Scholar
  • 106 Noris P, Klersy C, Zecca M , et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. J Thromb Haemost 2009; 7 (12) 2131-2136
    CrossrefPubMedSearch in Google Scholar
  • 107 Latger-Cannard V, Hoarau M, Salignac S, Baumgart D, Nurden P, Lecompte T. Mean platelet volume: comparison of three analysers towards standardization of platelet morphological phenotype. Int J Lab Hematol 2012; 34 (3) 300-310
    CrossrefPubMedSearch in Google Scholar
  • 108 Neunert C, Lim W, Crowther M, Cohen A, Solberg Jr L, Crowther MA. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16) 4190-4207
    CrossrefPubMedSearch in Google Scholar